Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016–Present)

Research Progress of Small Molecule VEGFR/c-Met Inhibitors as Anticancer Agents (2016–Present)

Vascular endothelial growth factor receptor 2 (VEGFR-2) binds to VEGFR-A, VEGFR-C and VEGFR-D and participates in the formation of tumor blood vessels, mediates the proliferation of endothelial cells, enhances microvascular permeability, and blocks apoptosis. Blocking or downregulating the signal tr...

Full description

Bibliographic Details
Main Authors:	Qian Zhang, Pengwu Zheng, Wufu Zhu
Format:	Article
Language:	English
Published:	MDPI AG 2020-06-01
Series:	Molecules
Subjects:	dual VEGFR/c-Met inhibitors anticancer agents research progress
Online Access:	https://www.mdpi.com/1420-3049/25/11/2666

Similar Items

In Silico Analysis of Triamterene as a Potential Dual Inhibitor of VEGFR-2 and c-Met Receptors
by: Stuart Lutimba, et al.
Published: (2024-12-01)

Exploring the potential of small molecules of dual c-Met and VEGFR inhibitors for advances and future drug discovery in cancer therapy
by: Sachin A. Dhawale, et al.
Published: (2024-09-01)

Design, Synthesis and Antitumor Activity of Novel Selenium-Containing Tepotinib Derivatives as Dual Inhibitors of c-Met and TrxR
by: Jinhui Hu, et al.
Published: (2023-01-01)

Discovery of sulfonamide-tethered isatin derivatives as novel anticancer agents and VEGFR-2 inhibitors
by: Moataz A. Shaldam, et al.
Published: (2023-12-01)

Pharmacophore screening, molecular docking, and MD simulations for identification of VEGFR-2 and c-Met potential dual inhibitors
by: Junmin Dong, et al.
Published: (2025-03-01)

Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors
by: Yu-Xiang Ma, et al.
Published: (2022-10-01)

Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with in vitro antitumor activity towards non-small lung cancer
by: Esraa A. Abdelsalam, et al.
Published: (2022-12-01)

Novel N-Arylmethyl-aniline/chalcone hybrids as potential VEGFR inhibitors: synthesis, biological evaluations, and molecular dynamic simulations
by: Hesham Haffez, et al.
Published: (2023-12-01)

In Vitro Anticancer Activity Screening of Novel Fused Thiophene Derivatives as VEGFR-2/AKT Dual Inhibitors and Apoptosis Inducers
by: Rana M. Abdelnaby, et al.
Published: (2022-06-01)

Comparison of small molecules VEGFR inhibitors in the treatment of renal cell carcinoma
by: Jie Yi Tan, et al.
Published: (2023-07-01)

The dual blockade of MET and VEGFR2 signaling demonstrates pronounced inhibition on tumor growth and metastasis of hepatocellular carcinoma
by: Yu Zhang, et al.
Published: (2018-04-01)

Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit
by: Chunjiang Wu, et al.
Published: (2015-10-01)

Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies
by: Abdulmalik S. Altamimi, et al.
Published: (2021-05-01)

Discovery of new nicotinamides as apoptotic VEGFR-2 inhibitors: virtual screening, synthesis, anti-proliferative, immunomodulatory, ADMET, toxicity, and molecular dynamic simulation studies
by: Reda G. Yousef, et al.
Published: (2022-12-01)

Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2
by: Reda G. Yousef, et al.
Published: (2022-06-01)

1,3,4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and in silico studies
by: Mohamed Hagras, et al.
Published: (2022-12-01)

Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation
by: Alaa Elwan, et al.
Published: (2022-08-01)

Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, in silico studies, and antiproliferative evaluation
by: Mohammed S. Taghour, et al.
Published: (2022-12-01)

Design, Synthesis, and Biological Evaluation of 2-Substituted Aniline Pyrimidine Derivatives as Potent Dual Mer/c-Met Inhibitors
by: Daowei Huang, et al.
Published: (2024-01-01)

Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis
by: Lei Wang, et al.
Published: (2024-01-01)

Computational Modeling to Quantify the Contributions of VEGFR1, VEGFR2, and Lateral Inhibition in Sprouting Angiogenesis
by: Clemens Kühn, et al.
Published: (2019-03-01)

Discovery of new thiazolidine-2,4-dione derivatives as potential VEGFR-2 inhibitors: In vitro and in silico studies
by: Ibrahim H. Eissa, et al.
Published: (2024-01-01)

Development of 3-methyl/3-(morpholinomethyl)benzofuran derivatives as novel antitumor agents towards non-small cell lung cancer cells
by: Mohammad M. Al-Sanea, et al.
Published: (2021-01-01)

Design and synthesis of phthalazine-based compounds as potent anticancer agents with potential antiangiogenic activity via VEGFR-2 inhibition
by: Salwa Elmeligie, et al.
Published: (2019-01-01)

Novel diaryl dihydropyrimidines as promising anticancer agents: In silico, in vitro investigation
by: Asief Mohammed, et al.
Published: (2024-08-01)

Identification of Novel Cyanopyridones and Pyrido[2,3-<em>d</em>]Pyrimidines as Anticancer Agents with Dual VEGFR-2/HER-2 Inhibitory Action: Synthesis, Biological Evaluation and Molecular Docking Studies
by: Tarfah Al-Warhi, et al.
Published: (2022-10-01)

Systemic hypertension with VEGFR inhibitor (axitinib) therapy in cancer patients: A meta-analysis and systematic review of randomized controlled trials
by: Aravind Dilli Babu, et al.
Published: (2024-06-01)

New Series of VEGFR-2 Inhibitors and Apoptosis Enhancers: Design, Synthesis and Biological Evaluation
by: Abdallah AE, et al.
Published: (2022-03-01)

Design and biological evaluation of 3-substituted quinazoline-2,4(1H,3H)-dione derivatives as dual c-Met/VEGFR-2-TK inhibitors
by: Abdelfattah Hassan, et al.
Published: (2023-12-01)

Design and synthesis of thiazolidine-2,4-diones hybrids with 1,2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: in-vitro anticancer evaluation and in-silico studies
by: Mohammed S. Taghour, et al.
Published: (2022-12-01)

Advances in MET tyrosine kinase inhibitors in gastric cancer
by: Yifan Zhang, et al.
Published: (2024-06-01)

Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile
by: Aml E.-S. Mghwary, et al.
Published: (2019-01-01)

Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: in vitro and in silico studies
by: Reda G. Yousef, et al.
Published: (2022-12-01)

Novel Phthalic-Based Anticancer Tyrosine Kinase Inhibitors: Design, Synthesis and Biological Activity
by: Elena Kalinichenko, et al.
Published: (2023-02-01)

VEGFA, VEGFR1, VEGFR2 serum and cerebrospinal fluid concentration in patients with acute leukemia
by: E. I. Zakharko, et al.
Published: (2024-04-01)

Potential inhibitors of VEGFR1, VEGFR2, and VEGFR3 developed through Deep Learning for the treatment of Cervical Cancer
by: Anuraj Nayarisseri, et al.
Published: (2024-06-01)

Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies
by: Sally C.M. Lau, MD, MPH, et al.
Published: (2023-10-01)

An Update on Synthesis of Coumarin Sulfonamides as Enzyme Inhibitors and Anticancer Agents
by: Laila Rubab, et al.
Published: (2022-02-01)

Virtual screening of anticancer activity of chalcones and pyrazolines as potential EGFR, VEGFR, and cytochrome P450 inhibitors
by: Hesti Lina Wiraswati, et al.
Published: (2023-07-01)

An Investigation of Vascular Endothelial Growth Factor (VEGFR-1 and VEGFR-2) in Burn Wound Healing
by: L Abdulazeem, et al.
Published: (2022-04-01)